. 2011 Dec 6;42(1):8–28. doi: 10.1007/s00595-011-0075-7

Table 5.

RCTs of postoperative adjuvant chemotherapy with PSK for resected colorectal cancer

References	Stage	No. of patients	Treatment	Percent survival/years	P value	Suggestive data (percent survival/years)
Torisu [88]	Stage III, IV	55	A: PSK B: Placebo	Improvement of DFS and OS	<0.05
Torisu [88]	Stage III, IV	56	A: PSK B: Placebo	Improvement of DFS and OS	<0.05
Takashima [89]	Dukes’ A–C	53	A: MMC + FT suppo + PSK B: MMC + FT suppo	91.4/6 80.8/6	0.139	A: 30 cases^a, 90.2/6 B: 39 cases^a, 70.9/6 P < 0.05
Takashima [89]	Dukes’ A–C	71	A: MMC + FT suppo + PSK B: MMC + FT suppo	91.4/6 80.8/6	0.139	A: 30 cases^a, 90.2/6 B: 39 cases^a, 70.9/6 P < 0.05
Mitomi [90]	Stage III	221	A: MMC+5-FU+PSK B: MMC+5-FU	78.5/5 69.7/5	0.0325
Mitomi [90]	Stage III	227	A: MMC+5-FU+PSK B: MMC+5-FU	78.5/5 69.7/5	0.0325
Ito [91]	Dukes’ C	220	A: 5-FU+PSK B: 5-FU	79.6/7 75.6/7	0.081	SCD A: 83.4/7 B: 78.5/7 P = 0.019
Ito [91]	Dukes’ C	221	A: 5-FU+PSK B: 5-FU	79.6/7 75.6/7	0.081	SCD A: 83.4/7 B: 78.5/7 P = 0.019
Ohwada [92]	Stage II, III	137	A: MMC+UFT+PSK B: MMC+UFT	81.8/5 72.1/5	0.056	DFS A: 73.0/5 B: 58.8/5 P=0.016
Ohwada [92]	Stage II, III	68	A: MMC+UFT+PSK B: MMC+UFT	81.8/5 72.1/5	0.056	DFS A: 73.0/5 B: 58.8/5 P=0.016

DFS disease-free survival, OS overall survival, MMC mitomycin C, FT tegafur, 5-FU 5-fluorouracil, SCD survival for cancer-related death, UFT tegafur-uracil

^aLymphatic vessel invasion (+)